We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pediatrix Medical Gears Up for Q4 Results: What to Expect?
Read MoreHide Full Article
Physician services provider Pediatrix Medical Group, Inc. (MD - Free Report) is set to report its fourth-quarter 2024 results on Feb. 20, 2025, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings and revenues is pegged at 37 cents per share and $485.68 million, respectively.
The earnings estimate for the to-be-reported quarter has remained stable over the past 60 days. The bottom-line projection indicates a year-over-year increase of 15.6%. However, the Zacks Consensus Estimate for quarterly revenues suggests a year-over-year decrease of 2.2%.
Image Source: Zacks Investment Research
For 2024, the Zacks Consensus Estimate for Pediatrix Medical’s revenues is pegged at $2 billion, implying a marginal rise of 0.1% year over year. The consensus mark for current year EPS is pegged at $1.35, implying a growth of 7.1% on a year-over-year basis.
Pediatrix Medical beat the consensus estimate for earnings in three of the trailing four quarters and met once, with the average surprise being 9.9%, as you can see below.
Pediatrix Medical Group, Inc. Price and EPS Surprise
However, our proven model does not conclusively predict an earnings beat for MD this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the chances of an earnings beat. That is not the case here, as you will see below.
MD has an Earnings ESP of 0.00% and a Zacks Rank #3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Let’s see how things have shaped up before the fourth-quarter earnings announcement.
Q4 Factors to Note for Pediatrix Medical
Both the Zacks Consensus Estimate and our model estimate for fourth-quarter net patient service revenue indicate a 2.2% year-over-year decline. Moreover, both the consensus mark and our model estimate for hospital contract administrative fees predict a 2% decline from a year ago. These are likely to have affected the company’s top line in the fourth quarter.
Nevertheless, the Zacks Consensus Estimate for same-facility revenue growth is pegged at 4.3% for the fourth quarter thanks to same-facility patient volume growth of 1.6% and same-facility net reimbursement growth of 2.7%.
Also, our model estimate for total operating expenses predicts a more than 26% year-over-year decline. Lower practice salaries & benefits, practice supplies & other expenses and G&A costs are likely to have aided its bottom line.
Our model estimate for fourth-quarter interest expense is pegged below $10 million, indicating a continued year-over-year decline in the metric. We expect Pediatrix Medical’s fourth-quarter net income to be above $22 million, a significant jump from the year-ago period.
How Did Other Stocks Perform?
Here are some stocks in the broader Medical space that have already reported earnings for this quarter: HCA Healthcare, Inc. (HCA - Free Report) , The Ensign Group, Inc. (ENSG - Free Report) and The Cigna Group (CI - Free Report) .
HCA Healthcare reported fourth-quarter 2024 adjusted EPS of $6.22, which outpaced the Zacks Consensus Estimate by 4.2%, driven byhigher patient volumes giving rise to an increased number of inpatient surgeries and same-facility emergency room visits. However, the upside was partly offset by elevated salaries and benefits expenses. Additional expenses due to Hurricane Helene and Hurricane Milton also impacted the results.
Ensign reported fourth-quarter 2024 adjusted earnings per share of $1.49, which outpaced the Zacks Consensus Estimate by 1.4% thanks to improved occupancy rates, higher patient days and higher skilled service revenues. The positives were partly offset by an elevated expense level, due to the higher cost of services and rents.
Cigna reported fourth-quarter 2024 adjusted earnings per share of $6.64, which missed the Zacks Consensus Estimate by 15.2% due to a decline in its overall medical customer base and elevated medical costs. Nevertheless, the downside was partly offset by expanding specialty volumes in the Evernorth Health Services segment and new client wins.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pediatrix Medical Gears Up for Q4 Results: What to Expect?
Physician services provider Pediatrix Medical Group, Inc. (MD - Free Report) is set to report its fourth-quarter 2024 results on Feb. 20, 2025, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings and revenues is pegged at 37 cents per share and $485.68 million, respectively.
See the Zacks Earnings Calendar to stay ahead of market-making news.
The earnings estimate for the to-be-reported quarter has remained stable over the past 60 days. The bottom-line projection indicates a year-over-year increase of 15.6%. However, the Zacks Consensus Estimate for quarterly revenues suggests a year-over-year decrease of 2.2%.
For 2024, the Zacks Consensus Estimate for Pediatrix Medical’s revenues is pegged at $2 billion, implying a marginal rise of 0.1% year over year. The consensus mark for current year EPS is pegged at $1.35, implying a growth of 7.1% on a year-over-year basis.
Pediatrix Medical beat the consensus estimate for earnings in three of the trailing four quarters and met once, with the average surprise being 9.9%, as you can see below.
Pediatrix Medical Group, Inc. Price and EPS Surprise
Pediatrix Medical Group, Inc. price-eps-surprise | Pediatrix Medical Group, Inc. Quote
Pediatrix Medical’s Q4 Earnings Whispers
However, our proven model does not conclusively predict an earnings beat for MD this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the chances of an earnings beat. That is not the case here, as you will see below.
MD has an Earnings ESP of 0.00% and a Zacks Rank #3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Let’s see how things have shaped up before the fourth-quarter earnings announcement.
Q4 Factors to Note for Pediatrix Medical
Both the Zacks Consensus Estimate and our model estimate for fourth-quarter net patient service revenue indicate a 2.2% year-over-year decline. Moreover, both the consensus mark and our model estimate for hospital contract administrative fees predict a 2% decline from a year ago. These are likely to have affected the company’s top line in the fourth quarter.
Nevertheless, the Zacks Consensus Estimate for same-facility revenue growth is pegged at 4.3% for the fourth quarter thanks to same-facility patient volume growth of 1.6% and same-facility net reimbursement growth of 2.7%.
Also, our model estimate for total operating expenses predicts a more than 26% year-over-year decline. Lower practice salaries & benefits, practice supplies & other expenses and G&A costs are likely to have aided its bottom line.
Our model estimate for fourth-quarter interest expense is pegged below $10 million, indicating a continued year-over-year decline in the metric. We expect Pediatrix Medical’s fourth-quarter net income to be above $22 million, a significant jump from the year-ago period.
How Did Other Stocks Perform?
Here are some stocks in the broader Medical space that have already reported earnings for this quarter: HCA Healthcare, Inc. (HCA - Free Report) , The Ensign Group, Inc. (ENSG - Free Report) and The Cigna Group (CI - Free Report) .
HCA Healthcare reported fourth-quarter 2024 adjusted EPS of $6.22, which outpaced the Zacks Consensus Estimate by 4.2%, driven byhigher patient volumes giving rise to an increased number of inpatient surgeries and same-facility emergency room visits. However, the upside was partly offset by elevated salaries and benefits expenses. Additional expenses due to Hurricane Helene and Hurricane Milton also impacted the results.
Ensign reported fourth-quarter 2024 adjusted earnings per share of $1.49, which outpaced the Zacks Consensus Estimate by 1.4% thanks to improved occupancy rates, higher patient days and higher skilled service revenues. The positives were partly offset by an elevated expense level, due to the higher cost of services and rents.
Cigna reported fourth-quarter 2024 adjusted earnings per share of $6.64, which missed the Zacks Consensus Estimate by 15.2% due to a decline in its overall medical customer base and elevated medical costs. Nevertheless, the downside was partly offset by expanding specialty volumes in the Evernorth Health Services segment and new client wins.